🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Evopoint Biosciences clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Evopoint Biosciences as lead sponsor. Synced 26 Sep 2026
9Current trials
7Recruiting now
4Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Evopoint Biosciences is the lead sponsor of 9 current clinical trials in our China and USA registers. 7 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are XNW28012, XNW5004 and CHOP. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting778%
  • Not yet open222%

Trials by phase

  • Phase 1/2556%
  • Phase 3222%
  • Phase 1111%
  • Phase 2111%
01

Clinical trials sponsored by Evopoint Biosciences

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
NCT07545603 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3
Drug: XNW5004
Phase 2 Recruiting 2026-02 China
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer
Drug: XNW28012
Phase 1/2 Recruiting 2023-12 China
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
NCT07730515 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma
Drugs: CHOP, XNW5004
Phase 1/2 Recruiting 2025-08 China
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
NCT06987500 · ClinicalTrials.gov ↗ · Tumor, Solid
Phase 1/2 Recruiting 2025-04 China
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT06702995 · ClinicalTrials.gov ↗ · Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Phase 1/2 Recruiting 2023-04 China
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT06776952 · ClinicalTrials.gov ↗ · Relapsed/Refractory Peripheral T Cell Lymphoma
Phase 3 Recruiting 2025-04 China
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Drug: XNW28012
Phase 3 Recruiting 2025-07 China
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
NCT07707674 · Metastatic Pancreatic Cancer
Drug: XNW28012
Phase 1 Not yet open 2026-07 USA
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
NCT07327294 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Not yet open 2026-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Evopoint Biosciences trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Evopoint Biosciences trials

16 conditions
Advanced Solid Tumors2Metastatic Pancreatic Cancer1Follicular Lymphoma, Grade 11Follicular Lymphoma, Grade 21Follicular Lymphoma, Grade 31Follicular Lymphoma Grade 3A1Pancreatic Carcinoma1Ovarian Cancer1Cervical Cancers1Non-hodgkin Lymphoma1Peripheral T-cell Lymphoma1Tumor, Solid1Metastatic Castrate-Resistant Prostate Cancer1mCRPC (Metastatic Castration-resistant Prostate Cancer)1Relapsed/Refractory Peripheral T Cell Lymphoma1Pancreatic Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China87
Clinical trials in USA10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Shanghai Hengrui Pharmaceutical6
Bristol-Myers Squibb5
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Hansoh BioMedical R&D Company4
Bayer3
Vividion Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about Evopoint Biosciences trials

How many clinical trials does Evopoint Biosciences sponsor?

Evopoint Biosciences is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Evopoint Biosciences trials recruiting?

Yes. 7 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Evopoint Biosciences testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are XNW28012 (3), XNW5004 (3), CHOP (1) and Enzalutamide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.